Stock Analysis, Dividends, Split History
BIOC / Biocept, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||274.22|
|Enterprise Value ($M)||274.22|
|Book Value ($M)||8.51|
|Book Value / Share||0.12|
|Price / Book||32.23|
|NCAV / Share||0.08|
|Price / NCAV||49.69|
|Common Shares Outstanding||68,038,349|
|Common Stock Shares Outstanding||35,183,743|
|Preferred Stock Shares Outstanding||0|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||-16.67|
|Return on Assets (ROA)||-2.85|
|Return on Equity (ROE)||-32.79|
|Income Statement (mra) ($M)|
|Development Services Net Revenue||0.00|
|Net Revenues From Non Contracted Payers||0.00|
|Sales Revenue Goods Gross||17,183,395.00|
|Net Revenue Recorded In Excess Of Commercial Cash Collections||1,139,000.00|
|Net Revenues From Contracted Payers||0.00|
|Earnings Per Share Diluted||-0.79|
|Earnings Per Share Basic||-0.79|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||-19.65|
|Cash from Investing||-1.40|
|Cash from Financing||-19.65|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1044378|
|09072V905 09072V904 09072V955 09072V204|
|SIC 8071 - Medical Laboratories|
Stock splits are used by Biocept, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2017-10-16 - Asif
Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” its current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic mutations that may qualify a subset of cancer patients for targeted therapy. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Biocept assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Biocept current assays and planned future assays focus on key solid tumor indications utilizing its Target-Selectors liquid biopsy technology platform for the biomarker anal...
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...
Related News Stories
The company noted the distribution of rights to acquire non-tradable units consisting of one preferred stock and 220 warrants. (6-1)
Biocept, Inc. (BIOC - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. The move came after the company entered into an agreement with Alliance Global FZ, LLC to market the former’s Target Selector liquid biopsy tests in the United Arab Emirates and other countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia region. (9-0)
Biocept stock (NASDAQ:BIOC) was skyrocketing on Friday as the company announced a biopsy testing partnership with Alliance Global FZ. (6-1)
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. [Operator Instructions] (21-4)
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept Fourth Quarter and Full Year 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session [Operator Instructions]. As a reminder, this conference call is being recorded today, March 28, 2018. (28-2)
Silicon Investor Message Boards
This table lists all message boards related to BIOC / Biocept, Inc. on message board site Silicon Investor.
as of ET